GALMED PHARMACEUTICALS LTD
GLMDNASDAQ🏆 #3758 by market capUS Equity
$0.57▲ $0.00 (+0.77%)
Live1h—
24h▲ 0.8%
7d▲ 0.0%
14d▲ 5.5%
30d▲ 1.9%
1y▼ 60.5%
🏦Market Cap
$5M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
2.2x
Cheap
Otter Score
42
Weak
Trading Snapshot
- Day Range
- $0.57 – $0.58
- 52-Week Range
- $0.41 – $1.65
- Volume
- $3.20B
- Avg Volume
- $3.93B
- Shares Outstanding
- 8.3M
- Next Earnings
- Sep 12, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $527,982
- P/E Ratio
- —
- P/S Ratio
- 2.2x
- EPS (TTM)
- $-2.07
- Dividend Yield
- —
Why Investors Own GLMD
- ✓High-growth profile — revenue up +16.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 26% gross margin and 23% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$2M▲ +16.7% YoY
Gross Margin (TTM)
26.2%▲ +0.0% YoY
Operating Income (TTM)
$505,326▲ +16.7% YoY
Free Cash Flow (TTM)
$525,813▲ +16.7% YoY
About GALMED PHARMACEUTICALS LTD
A company profile for GALMED PHARMACEUTICALS LTD isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
42/100
Analyst Price Target
ⓘAverage Target
$0.74
▲ +28.6% Upside
High Target$0.85
Low Target$0.67
Based on 31 analysts
Latest News & Updates
🚀
Barron’s·2h ago
GALMED PHARMACEUTICALS LTD tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift GLMD price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Reuters·1d ago
GALMED PHARMACEUTICALS LTD announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.